Development of a CHO cell culture platform for monoclonal antibod | 7464
Journal of Glycobiology

Journal of Glycobiology
Open Access

ISSN: 2168-958X

Development of a CHO cell culture platform for monoclonal antibody production: from clone generation to pilot-plant scale-up

2nd Glycobiology World Congress

August 29-31, 2016 Atlanta, USA

Yves Durocher

National Research Council Canada, Canada

Posters & Accepted Abstracts: J Glycobiol

Abstract :

The National Research Council Canada (NRC) has developed an inducible CHOBRI cell line platform, employing a generic approach for the fast development of monoclonal antibodies (mAbs) or therapeutic proteins production processes. Starting from CHO pools that can produce gram quantities of mAbs, clones are selected and process conditions are optimized for scale-up to a pilot plant scale production (20-200L). The final process delivers material for toxicity studies and can seamlessly be transferred to a GMP production facility.

Biography :

Yves Durocher is a Research Officer at the National Research Council of Canada since 1995. He obtained his PhD in Biochemistry at the Université de Montréal in 1993. He manages the NRC’s Mammalian Cell Culture Section which is composed of 33 scientists involved in protein expression and CHO cell line development for internal projects and external clients. His research activities have been focused on the development the of large-scale transient gene expression (LSTGE) platforms using HEK293 and CHO cells for protein production and on the development of stable CHO pool and clonal cell line platforms for the manufacturing of recombinant therapeutic proteins. He also contributed to ~100 scientific publications in peer-reviewed journals.